DMRA Damora Therapeutics, Inc.
Nasdaq · SEC CIK 1800315 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $30.7K 4 sales by 3 insiders
- Filings on record
- 82 since 2021-08-19, latest 2026-08-13 17:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Schambye Hans T. | CEO, Dir | — | $15.0K |
| Winslow Garrett | GC | — | $12.8K |
| Firmani Lori | CFO | — | $2,890 |
| Sattarzadeh Sherwin | COO | — | — |
| Bruno Julianne | Dir | — | — |
| Hewes L. Becker | Chief Medical Off | — | — |
| Fairmount Healthcare Fund II L.P. | 10% | — | — |
| Jarrett Jennifer | See Remarks, Dir | — | — |
Transactions 39
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-07-07 20:00 | 2026-07-03 | DMRA | Winslow Garrett | GC | M - OptEx | — | +680 | 2,534 | +37% | — |
| D | 2026-07-07 20:00 | 2026-07-06 | DMRA | Winslow Garrett | GC | S - Sale+OE | $29.98 | -245 | 2,289 | -10% | -$7,345 |
| D | 2026-04-01 17:30 | 2026-03-30 | DMRA | Jarrett Jennifer | See Remarks, Dir | A - Grant | $0.00 | +500.0K | 500.0K | New | $0 |
| DMI | 2026-02-12 | 2026-02-09 | DMRA | Fairmount Healthcare Fund II L.P. | 10% | M - OptEx | $0.00 | +8.71M | 2.90M | New | $0 |
| D | 2026-02-12 | 2026-02-09 | DMRA | Bruno Julianne | Dir | M - OptEx | $0.00 | +129.0K | 137.0K | +1,606% | $0 |
| D | 2026-01-26 | 2026-01-05 | DMRA | Sattarzadeh Sherwin | COO | A - Grant | $0.00 | +190.4K | 190.4K | New | $0 |
| D | 2026-01-07 | 2026-01-05 | DMRA | Hewes L. Becker | Chief Medical Off | A - Grant | $0.00 | +264.6K | 264.6K | New | $0 |
| D | 2026-01-06 | 2026-01-02 | DMRA | Winslow Garrett | GC | S - Sale+OE | $21.38 | -255 | 1,854 | -12% | -$5,452 |
| D | 2026-01-06 | 2026-01-02 | DMRA | Winslow Garrett | GC | M - OptEx | — | +680 | 2,109 | +48% | — |
| D | 2026-01-06 | 2026-01-02 | DMRA | Firmani Lori | CFO | M - OptEx | — | +374 | 1,066 | +54% | — |
| D | 2026-01-06 | 2026-01-02 | DMRA | Firmani Lori | CFO | S - Sale+OE | $21.41 | -135 | 931 | -13% | -$2,890 |
| D | 2026-01-06 | 2026-01-02 | DMRA | Schambye Hans T. | CEO, Dir | M - OptEx | — | +1,360 | 5,382 | +34% | — |
| D | 2026-01-06 | 2026-01-02 | DMRA | Schambye Hans T. | CEO, Dir | S - Sale+OE | $21.38 | -700 | 4,682 | -13% | -$15.0K |
| D | 2025-07-08 | 2025-07-03 | DMRA | Firmani Lori | Interim CFO | M - OptEx | — | +374 | 839 | +80% | — |
| D | 2025-07-08 | 2025-07-03 | DMRA | Firmani Lori | Interim CFO | S - Sale+OE | $3.39 | -147 | 692 | -18% | -$498.33 |
| D | 2025-07-08 | 2025-07-03 | DMRA | Winslow Garrett | GC | M - OptEx | — | +680 | 1,689 | +67% | — |
| D | 2025-07-08 | 2025-07-03 | DMRA | Winslow Garrett | GC | S - Sale+OE | $3.39 | -260 | 1,429 | -15% | -$881.40 |
| D | 2025-07-08 | 2025-07-03 | DMRA | Schambye Hans T. | CEO, Dir | S - Sale+OE | $3.38 | -735 | 4,022 | -15% | -$2,484 |
| D | 2025-07-08 | 2025-07-03 | DMRA | Schambye Hans T. | CEO, Dir | M - OptEx | — | +1,360 | 4,757 | +40% | — |
| D | 2025-01-07 | 2025-01-03 | DMRA | Firmani Lori | Interim CFO | M - OptEx | — | +726 | 726 | New | — |
| D | 2025-01-07 | 2025-01-03 | DMRA | Firmani Lori | Interim CFO | S - Sale+OE | $5.63 | -261 | 465 | -36% | -$1,469 |
| D | 2025-01-07 | 2025-01-03 | DMRA | Winslow Garrett | GC | M - OptEx | — | +1,320 | 1,480 | +825% | — |
| D | 2025-01-07 | 2025-01-03 | DMRA | Winslow Garrett | GC | S - Sale+OE | $5.60 | -471 | 1,009 | -32% | -$2,638 |
| D | 2025-01-07 | 2025-01-03 | DMRA | Schambye Hans T. | CEO, Dir | M - OptEx | — | +2,640 | 4,738 | +126% | — |
| D | 2025-01-07 | 2025-01-03 | DMRA | Schambye Hans T. | CEO, Dir | S - Sale+OE | $5.60 | -1,341 | 3,397 | -28% | -$7,510 |
| MI | 2023-08-17 | 2023-08-15 | DMRA | OrbiMed Advisors Israel II Ltd | 10% | S - Sale | $0.75 | -822.7K | 631.0K | -57% | -$617.0K |
| MI | 2023-08-02 | 2023-07-31 | DMRA | OrbiMed Capital GP VII LLC | 10% | S - Sale | $3.00 | -209.4K | 2.11M | -9% | -$628.2K |
| MI | 2023-07-27 | 2023-07-25 | DMRA | OrbiMed Capital GP VII LLC | 10% | S - Sale | $2.92 | -39.2K | 909.6K | -4% | -$114.5K |
| MI | 2023-07-17 | 2023-07-13 | DMRA | OrbiMed Advisors Israel II Ltd | 10% | S - Sale | $2.40 | -194.7K | 914.3K | -18% | -$467.3K |
| MI | 2023-04-17 | 2023-04-13+ | DMRA | ORBIMED ADVISORS LLC | 10% | S - Sale | $1.87 | -68.5K | 179.8K | -28% | -$128.3K |
| MI | 2023-04-12 | 2023-04-10+ | DMRA | OrbiMed Advisors Israel II Ltd | 10% | S - Sale | $1.80 | -67.5K | 985.6K | -6% | -$121.4K |
| MI | 2023-04-07 | 2023-04-05+ | DMRA | OrbiMed Genesis GP LLC | 10% | S - Sale | $2.16 | -102.6K | 186.6K | -35% | -$222.0K |
| 2022-03-23 | 2022-03-22 | DMRA | Schambye Hans T. | CEO, Dir | P - Purchase | $2.15 | +5,000 | 52.4K | +11% | +$10.8K | |
| 2022-03-23 | 2022-03-22 | DMRA | Lindmark Bertil | Chief Medical Off | P - Purchase | $2.16 | +14.6K | 16.6K | +730% | +$31.5K | |
| 2021-12-06 | 2021-12-03 | DMRA | Freve Jonathan | CFO | P - Purchase | $2.49 | +4,000 | 12.0K | +50% | +$9,960 | |
| 2021-12-06 | 2021-12-03 | DMRA | Winslow Garrett | GC | P - Purchase | $2.48 | +2,000 | 4,000 | +100% | +$4,960 | |
| 2021-11-10 | 2021-11-09 | DMRA | Schambye Hans T. | CEO, Dir | P - Purchase | $3.50 | +4,500 | 47.4K | +10% | +$15.8K | |
| 2021-11-09 | 2021-11-08 | DMRA | Freve Jonathan | CFO | P - Purchase | $3.40 | +3,000 | 8,000 | +60% | +$10.2K | |
| 2021-08-19 | 2021-08-18 | DMRA | Freve Jonathan | CFO | P - Purchase | $3.92 | +3,000 | 5,000 | +150% | +$11.8K |